LOS ANGELES--(BUSINESS WIRE)--In light of the recently announced plan to put 2.5 million people on injectable pre-exposure prophylaxis (PrEP), specifically lenacapavir, by 2027, AIDS Healthcare ...

– New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo ®) was Effective and Well Tolerated Across a Broad Range of Populations, Including Pregnant and Lactating Women, ...

CVS is now covering long-acting injectable PrEP, representing a shift from last year when the pharmacy giant announced it was ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden administration announced October 21. The news comes just weeks after it was announced ...

A recent study has found that lenacapavir, an injectable medication administered twice a year, is more effective at preventing HIV among gay, bisexual, and transgender people than a daily regimen of ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully passed an important early safety trial. Researchers have shared that the drug ...

Findings showed 99.9% of participants in the lenacapavir group did not acquire HIV infection. Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil ...

The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an injectable form of the HIV prevention medication known as PrEP, marking a ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. The new rule, built on ...

Patients can now receive long acting injectables to advance closing the gap in HIV prevention. In a major step toward HIV prevention, CAN Community Health, the nation’s leading resource in ending ...

The first ever injectable drug that can prevent HIV has been approved for use in England and Wales. Subscribe to our newsletter for the latest sci-tech news updates. The drug, cabotegravir, would ...